Phaseline

Companies › Shanghai Yidian Pharmaceutical Technology Development

Shanghai Yidian Pharmaceutical Technology Development: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 5 Phase 2, 1 Phase 1; Respiratory, Other, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YD0743–Phase 2SepsisDec 2026
HL-1186–Phase 2Moderate to Severe Acute Postoperative Pain; Postherpetic Neuralgia ( PHN ); Healthy ParticipantsJun 2027
HTMC0658–Phase 2Chronic Sinusitis Without Nasal Polyps–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06912295HL-1186Phase 1Healthy ParticipantsOtherAug 2025
NCT07147049HL-1186Phase 2Moderate to Severe Acute Postoperative PainOtherDec 2025
NCT07311369HL-1186Phase 2Moderate to Severe Acute Postoperative PainOtherFeb 2026
NCT07174115HTMC0658Phase 2Chronic Sinusitis Without Nasal PolypsRespiratoryApr 2026
NCT07413094YD0743Phase 2SepsisInfectious diseaseDec 2026
NCT07758920HL-1186Phase 2Postherpetic Neuralgia ( PHN )OtherJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

BioAegis Therapeutics Freya Biosciences ApS Mundipharma Research Shanghai Synvida Biotechnology Aligos Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.